From the Mayo Clinic Center for Innovation (Dr. Romero-Brufau) Department of Medicine (Drs. Manning, Borrud, Keller, Kashiwagi, Huddleston, and Croghan) Department of Health Sciences Research (Mr. Cha), Mayo Clinic, Rochester, MN.
Abstract
- Objective: To determine whether a score of 8 or greater on the I-MOVE, a bedside instrument that evaluates the need for assistance in turning, sitting, standing, transferring from bed to a chair, and ambulating, predicts lower risk for 30-day readmission or mortality.
- Design: Retrospective cohort study of patients discharged from 2003 to 2011 from a referral hospital in Southeastern Minnesota. We used a convenience sample of 426 inpatients who had at least one documented calculation of the I-MOVE score performed as part of the clinical process during the study.
- Results: Overall 30-day mortality rate, readmission rate, and rate of the combined death/readmission outcome were 6.1% (26 patients), 15% (64 patients) and 19.7% (84 patients), respectively. After controlling for confounding variables, an I-MOVE score ≥ 8 was a significant predictive factor for 30-day mortality (OR = 0.136, P < 0.01) but not 30-day readmission (OR = 1.143, P = 0.62) or the combined outcome death/readmission (OR = 0.682, P = 0.13).
- Conclusion: The clinical information provided by a patient's I-MOVE score before discharge does not provide information about readmission risk but may offer incremental information about 30-day mortality risk.
Risk factors for hospital 30-day readmission have been studied by Hasan et al [1], van Walraven et al [2], Allaudeen et al [3], and more recently, Donze et al [4]. Risk factors found to be associated with readmission include race, length of stay, and number of hospitalizations in the last 12 months. Additionally, patients identified “feeling unprepared for discharge” and “difficulty performing activities of daily living” as top issues contributing to readmission. The Affordable Care Act established the Value-Based Purchasing (VBP) model for defined hospital illnesses such as acute myocardial infarction, heart failure, and community acquired pneumonia. This has focused more attention on post-discharge 30-day mortality and readmissions as publicly reported metrics that in part determine the Centers for Medicare and Medicaid Services care reimbursement rates [5].
The Independent Mobility Validation Evaluation (I-MOVE) [6] is a bedside discharge tool for assessing the need for assistance in turning, sitting, standing, transferring from bed to a chair, and ambulating. It was designed as a discharge planning tool for clinicians, particularly in the situation of an elder hoping to return home alone. I-MOVE was shown to have face and content validity, and very good inter-observer reliability (r = 0.91) [6], and it requires only a few minutes to administer without any special apparatus. The Figure shows the tasks and the grading system, which awards points for higher function, from a score of 1 (requires assistance to turn in bed) to 12 (walks in the hallway independently). Recently, a modified (self-starting and self-reported) form of I-MOVE was employed in a cloud-based iPad application MyCare for 150 recovering heart surgery patients in whom higher (first day in general care unit after transfer from intensive care) I-MOVE scores were associated with shorter length of stay [7].In our hospital, over 400 inpatients have been evaluated since 2004 using the I-MOVE scoring system in the course of their usual care. I-MOVE was most commonly employed by geriatricians in the division of hospital internal medicine, who collectively endorsed the tool in their practice meetings, especially for elderly patients returning to home alone whose mobility independence was uncertain.